Shelby Tucker's questions to Allogene Therapeutics (ALLO) leadership • Q2 2025
Question
Shelby Tucker, on for Luca Aci at RBC Capital Markets, questioned if the recent patient death in the first-line setting could materially slow trial enrollment, given the patient population is perceived as relatively stable.
Answer
CMO Dr. Zachary Roberts countered that MRD-positive patients have chemo-refractory cancer and are at high risk of progression, a view shared by investigators. He explained the unfortunate event prompted a safety and efficacy review that ultimately gave the team, DSMB, and FDA confidence that moving forward with the standard FC arm provides the appropriate benefit-risk profile.